News from Zyme and the companies we work with.

December 17, 18

Horizon Discovery Group plc enters an exclusive partnership with C4X Discovery Holdings plc to validate targets and develop next-generation oncology drugs

Cambridge, UK, 17 December 2018: Horizon Discovery Group plc (AIM: HZD), a global leader in the application of gene editing and gene modulation technologies, today announces that it has entered into an exclusive target discovery partnership with C4X Discovery Holdings … Continue reading →

December 12, 18

Avacta appoints Dr Jose Saro as Chief Medical Officer

Dr Jose Saro joins Avacta from Roche to lead the Group’s Affimer® therapeutic development strategy and drive the in-house programmes into the clinic Cambridge, UK, 12 December 2018: Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, … Continue reading →

December 11, 18

IONTAS founder and phage display pioneer attends Nobel Prize Award Ceremony

Dr John McCafferty celebrates success of phage display technology with Nobel Prize in Chemistry Laureates  Cambridge, UK, 11 December 2018: IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, announced its Founder and Chief Executive … Continue reading →

December 10, 18

Avacta and LG Chem Life Sciences agree multi-target Affimer therapeutics development alliance

Cambridge, UK and Seoul, South Korea, 10 December 2018: Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, and LG Chem Life Sciences, the life sciences division of the South Korean LG Group, today announced a multi-target … Continue reading →

December 4, 18

Concept Life Sciences forms Scientific Advisory Board

SAB will help to guide Concept Life Sciences’ scientific strategy for its drug discovery and development services business SAB Members are leading experts in a diverse range of therapeutic areas  Manchester, UK, 04 December 2018: Concept Life Sciences (“Concept”), the … Continue reading →

November 26, 18

Cobra Biologics, Pall Corporation and the Cell and Gene Therapy Catapult Win £1.5M Innovate UK Grant to Investigate Continuous Manufacturing for Gene Therapies

Keele, UK, Port Washington, USA, and London, UK, 26 November 2018: Cobra Biologics (Cobra), an international contract development and manufacturing organisation (CDMO) with a focus on advanced therapy medicinal products (ATMPs) has won a £1.5m shared grant from Innovate UK, … Continue reading →

November 9, 18

Concept Life Sciences extends GLP accreditation to support regulatory studies

MHRA confirms GLP extension at Dundee and Bradford sites Accreditation ensures quality and integrity of non-clinical laboratory studies to support agrichemical, biocide and chemical industries  Manchester and Dundee, UK, 07 November 2018: Concept Life Sciences (“Concept”), the integrated drug discovery … Continue reading →

November 9, 18

Concept Life Sciences extends GLP accreditation to support regulatory studies

MHRA confirms GLP extension at Dundee and Bradford sites Accreditation ensures quality and integrity of non-clinical laboratory studies to support pharmaceutical and biotech industries Manchester and Dundee, UK, 07 November 2018:   Concept Life Sciences (“Concept”), the integrated drug discovery and development … Continue reading →

November 7, 18

Expedeon AG signs supply and license agreement with Quanterix Corporation for access to proprietary immunoassay technology

Expedeon’s proprietary immunoassay technology to be incorporated into Quanterix’ Simoa Planar Immunoassay products Heidelberg, Germany and Cambridge, UK, 07 November 2018   –  Expedeon AG (Frankfurt: EXN; ISIN: DE000A1RFM03; Prime Standard) today announced a supply and license agreement with United States … Continue reading →

November 6, 18

Optibrium and University of Nottingham Collaborate on Innovative Teaching Programme

Provides students with the opportunity to design new drug-like molecules targeting fibrotic diseases and malaria with cutting-edge drug discovery software CAMBRIDGE and NOTTINGHAM, UK, 5th November 2018 – Optibrium™, a developer of software for drug discovery, today announced it had … Continue reading →